Systemic interferon gamma treatment in severe atopic dermatitis
Background: Recent results suggest decreased interferon gamma (IFN-γ) but high interleukin 4 (IL-4) production in patients with atopic dermatitis (AD). Because the relative activities of IL-4 and IFN-γ seem to regulate the amplitude of the IgE response we suggested a role for IFN-γ in the treatment...
Saved in:
Published in | Journal of the American Academy of Dermatology Vol. 29; no. 1; pp. 58 - 63 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Mosby, Inc
01.07.1993
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background:
Recent results suggest decreased interferon gamma (IFN-γ) but high interleukin 4 (IL-4) production in patients with atopic dermatitis (AD). Because the relative activities of IL-4 and IFN-γ seem to regulate the amplitude of the IgE response we suggested a role for IFN-γ in the treatment of AD.
Objective:
The purpose of this study was to assess the efficacy of systemic IFN-γ treatment in patients with severe AD.
Methods:
Patients with severe AD (
n = 14) were treated with recombinant IFN-γ for 6 weeks. During the study only basic local therapy with steroid-free hydrophilic or emollient ointments was allowed.
Results:
Eight patients (57%) showed marked clinical improvement during systemic IFN-γ therapy, Four of these patients showed continuous improvement 3 months after treatment was discontinued. Mean total and antigen-specific serum IgE concentrations were not statistically different during and after treatment, whereas mean spontaneous IgE production in vitro was significantly lower after 6 weeks of IFN-γ therapy.
Conclusion:
Our results suggest that IFN-γ treatment may represent a novel therapeutic approach in patients with severe AD. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0190-9622 1097-6787 |
DOI: | 10.1016/0190-9622(93)70152-J |